BRPI0719816B8 - uso do fator de crescimento epidérmico (egf) humano para preparar uma composição farmacêutica injetável para a restauração morfofuncional de nervos periféricos em neuropatia diabética e a referida composição - Google Patents
uso do fator de crescimento epidérmico (egf) humano para preparar uma composição farmacêutica injetável para a restauração morfofuncional de nervos periféricos em neuropatia diabética e a referida composiçãoInfo
- Publication number
- BRPI0719816B8 BRPI0719816B8 BRPI0719816A BRPI0719816A BRPI0719816B8 BR PI0719816 B8 BRPI0719816 B8 BR PI0719816B8 BR PI0719816 A BRPI0719816 A BR PI0719816A BR PI0719816 A BRPI0719816 A BR PI0719816A BR PI0719816 B8 BRPI0719816 B8 BR PI0719816B8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- peripheral nerves
- growth factor
- egf
- epidermal growth
- Prior art date
Links
- 210000000578 peripheral nerve Anatomy 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 title 1
- 229940116978 human epidermal growth factor Drugs 0.000 title 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 title 1
- 206010029240 Neuritis Diseases 0.000 abstract 2
- 230000000302 ischemic effect Effects 0.000 abstract 2
- 201000001119 neuropathy Diseases 0.000 abstract 2
- 230000007823 neuropathy Effects 0.000 abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 2
- 230000001953 sensory effect Effects 0.000 abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 210000000609 ganglia Anatomy 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
uso do fator de crescimento epidérmico para a restauração morfofuncional de nervos perifêricos em neuropatia diabética. a presente invenção refere-se à medicina humana, e, particularmente, ao uso do fator de crescimento epidérmico (egf) em uma composição farmacêutica, sendo a dita composição administrada por infiltração na periferia de.troncos e/ou gânglios nervosos, para.a restauração morfofuncional de nervos periféricos em neuropatia sensorial e motora, bem como neurite isquêmica. a presente invenção refere:--se também a uma composição que contém egf, onde esta molécula pode ser formulada junto com l fármacos anestésicos ou analgésicos, ou encapsulada em microsferas, e seu uso para a restauração morfofuncional de nervos periféricos em neuropatia sensorial e motora dolorosa, bem como em neurite isquêmica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2006-0192 | 2006-10-03 | ||
| CU20060192A CU23526B6 (es) | 2006-10-03 | 2006-10-03 | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| PCT/CU2007/000018 WO2008040260A1 (es) | 2006-10-03 | 2007-10-01 | Uso del factor de crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0719816A2 BRPI0719816A2 (pt) | 2015-09-08 |
| BRPI0719816B1 BRPI0719816B1 (pt) | 2018-04-24 |
| BRPI0719816B8 true BRPI0719816B8 (pt) | 2021-05-25 |
Family
ID=38925545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0719816A BRPI0719816B8 (pt) | 2006-10-03 | 2007-10-01 | uso do fator de crescimento epidérmico (egf) humano para preparar uma composição farmacêutica injetável para a restauração morfofuncional de nervos periféricos em neuropatia diabética e a referida composição |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8642552B2 (pt) |
| EP (1) | EP2075004B1 (pt) |
| JP (1) | JP5508853B2 (pt) |
| KR (1) | KR101464208B1 (pt) |
| CN (1) | CN101573130B (pt) |
| AR (1) | AR063088A1 (pt) |
| AT (1) | ATE544462T1 (pt) |
| AU (1) | AU2007304640B2 (pt) |
| BR (1) | BRPI0719816B8 (pt) |
| CA (1) | CA2665117C (pt) |
| CL (1) | CL2007002862A1 (pt) |
| CU (1) | CU23526B6 (pt) |
| DK (1) | DK2075004T3 (pt) |
| ES (1) | ES2386058T3 (pt) |
| MX (1) | MX2009003678A (pt) |
| PL (1) | PL2075004T3 (pt) |
| PT (1) | PT2075004E (pt) |
| RU (1) | RU2460536C2 (pt) |
| WO (1) | WO2008040260A1 (pt) |
| ZA (1) | ZA200902311B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101252740B1 (ko) * | 2011-05-25 | 2013-04-11 | 연세대학교 산학협력단 | 센서 및 센싱방법 |
| EP2737895A1 (en) * | 2012-11-30 | 2014-06-04 | Praxis Pharmaceutical, S.A. | Microparticles with EGF, method of preparation and use |
| US20150320861A1 (en) * | 2012-12-21 | 2015-11-12 | Sykehuset Sørlandet Hf | Egfr targeted therapy of neurological disorders and pain |
| CA2920835A1 (en) | 2013-08-20 | 2015-02-26 | Anutra Medical, Inc. | Syringe fill system and method |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
| USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
| USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
| MX391067B (es) | 2014-10-01 | 2025-03-21 | Eagle Biologics Inc | Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad. |
| RU2585421C1 (ru) * | 2014-12-24 | 2016-05-27 | Артур Владимирович Маргасов | Способ восстановления поврежденного нерва |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5130298A (en) * | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| SE9601243D0 (sv) * | 1996-03-29 | 1996-03-29 | Hans Arne Hansson | Promotion of regeneration of organized tissues |
| WO1999036513A1 (en) * | 1998-01-20 | 1999-07-22 | Aurx, Inc. | A herpes virus vector |
| US6444205B2 (en) * | 1998-09-30 | 2002-09-03 | Diacrin, Inc. | Transplantation of neural cells for the treatment of chronic pain or spasticity |
| SE9804064D0 (sv) | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| DE60021360T2 (de) * | 1999-04-15 | 2006-05-24 | Caritas St. Elizabeth's Medical Center of Boston, Inc., Boston | Vegf angiogenische wachstumsfaktoren zur behandlung von peripherer neuropathie |
| WO2002012335A2 (en) * | 2000-08-10 | 2002-02-14 | Pharmacia Corporation | A NEW EGF MOTIF REPEAT PROTEIN OBTAINED FROM A cDNA LIBRARY FROM HS-5 STROMAL CELL LINE |
| CU23157A1 (es) | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| ATE365561T1 (de) * | 2001-03-12 | 2007-07-15 | Inst Of Gene And Brain Science | Verwendung von interleukin-12 zur behandlung von nervenschäden |
| JP2006152001A (ja) * | 2001-03-12 | 2006-06-15 | Institute Of Gene & Brain Science | 神経損傷の治療薬 |
| CU23043A1 (es) * | 2001-12-20 | 2005-05-20 | Ct Ingenieria Genetica Biotech | Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
| US7465463B2 (en) * | 2002-09-04 | 2008-12-16 | Polyheal, Ltd. | Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
| WO2004084819A2 (en) * | 2003-03-19 | 2004-10-07 | University Of Kentucky Research Foundation | Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres |
| ES2354304T3 (es) * | 2003-04-25 | 2011-03-11 | The University Of Pittsburgh | Células derivadas del músculo (mdcs) para promover y potenciar la regeneración y reparación de nervios. |
| JP2008509093A (ja) * | 2004-08-06 | 2008-03-27 | ノヴォザイムズ グロペップ リミテッド | 糖尿病治療法 |
| MX2007008826A (es) | 2005-01-21 | 2007-11-15 | Univ Northwestern | Metodos y composiciones para encapsulacion de celulas. |
| KR100765496B1 (ko) * | 2005-12-09 | 2007-10-10 | 경희대학교 산학협력단 | 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물 |
-
2006
- 2006-10-03 CU CU20060192A patent/CU23526B6/es active IP Right Grant
-
2007
- 2007-10-01 CN CN2007800422158A patent/CN101573130B/zh not_active Expired - Fee Related
- 2007-10-01 CA CA2665117A patent/CA2665117C/en not_active Expired - Fee Related
- 2007-10-01 RU RU2009116646/15A patent/RU2460536C2/ru active
- 2007-10-01 MX MX2009003678A patent/MX2009003678A/es active IP Right Grant
- 2007-10-01 PT PT07817382T patent/PT2075004E/pt unknown
- 2007-10-01 EP EP07817382A patent/EP2075004B1/en not_active Not-in-force
- 2007-10-01 DK DK07817382.0T patent/DK2075004T3/da active
- 2007-10-01 ES ES07817382T patent/ES2386058T3/es active Active
- 2007-10-01 US US12/443,837 patent/US8642552B2/en active Active
- 2007-10-01 BR BRPI0719816A patent/BRPI0719816B8/pt not_active IP Right Cessation
- 2007-10-01 PL PL07817382T patent/PL2075004T3/pl unknown
- 2007-10-01 JP JP2009530751A patent/JP5508853B2/ja active Active
- 2007-10-01 AU AU2007304640A patent/AU2007304640B2/en not_active Ceased
- 2007-10-01 WO PCT/CU2007/000018 patent/WO2008040260A1/es not_active Ceased
- 2007-10-01 AT AT07817382T patent/ATE544462T1/de active
- 2007-10-01 AR ARP070104350A patent/AR063088A1/es unknown
- 2007-10-01 KR KR1020097009188A patent/KR101464208B1/ko not_active Expired - Fee Related
- 2007-10-03 CL CL200702862A patent/CL2007002862A1/es unknown
-
2009
- 2009-04-02 ZA ZA200902311A patent/ZA200902311B/xx unknown
-
2013
- 2013-12-26 US US14/140,849 patent/US9034826B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2075004A1 (en) | 2009-07-01 |
| CA2665117A1 (en) | 2008-04-10 |
| US8642552B2 (en) | 2014-02-04 |
| CA2665117C (en) | 2015-04-14 |
| US9034826B2 (en) | 2015-05-19 |
| PL2075004T3 (pl) | 2012-09-28 |
| CN101573130B (zh) | 2012-10-31 |
| CL2007002862A1 (es) | 2008-05-23 |
| CN101573130A (zh) | 2009-11-04 |
| RU2009116646A (ru) | 2010-11-10 |
| BRPI0719816B1 (pt) | 2018-04-24 |
| ATE544462T1 (de) | 2012-02-15 |
| MX2009003678A (es) | 2009-04-22 |
| ZA200902311B (en) | 2010-04-28 |
| JP2010505773A (ja) | 2010-02-25 |
| AU2007304640B2 (en) | 2013-01-17 |
| KR20090103862A (ko) | 2009-10-01 |
| DK2075004T3 (da) | 2012-05-14 |
| AU2007304640A1 (en) | 2008-04-10 |
| EP2075004B1 (en) | 2012-02-08 |
| US20140105990A1 (en) | 2014-04-17 |
| WO2008040260A1 (es) | 2008-04-10 |
| US20100136062A1 (en) | 2010-06-03 |
| JP5508853B2 (ja) | 2014-06-04 |
| BRPI0719816A2 (pt) | 2015-09-08 |
| PT2075004E (pt) | 2012-05-02 |
| ES2386058T3 (es) | 2012-08-08 |
| AR063088A1 (es) | 2008-12-23 |
| RU2460536C2 (ru) | 2012-09-10 |
| KR101464208B1 (ko) | 2014-12-04 |
| CU23526B6 (es) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0719816B8 (pt) | uso do fator de crescimento epidérmico (egf) humano para preparar uma composição farmacêutica injetável para a restauração morfofuncional de nervos periféricos em neuropatia diabética e a referida composição | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| BR112014006684A2 (pt) | análogos de glucagon | |
| BRPI0910832B8 (pt) | derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos. | |
| BR112016002171A2 (pt) | método, composição estéril e injetável e método para preparar uma composição estéril e injetável | |
| UY32237A (es) | Compuestos de arilo con sustituyentes heterociclicos y su uso | |
| UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
| CL2012003171A1 (es) | Compuestos derivados de ciclohexilamina, con actividad dual agonista con el receptor m3 muscarinico y agonista con el receptor b2 adrenérgicos; composición farmacéutica que comprende un compuesto; combinación; farmaceutica; y su uso de un compuesto en la preparacion de medicamento de enfermedades respiratorias. | |
| BR112015024659A8 (pt) | formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| MX338746B (es) | Vitamina d3 y analogos de la misma para tratar alopecia. | |
| CO2019006017A2 (es) | Composiciones farmacéuticas que contienen insulina | |
| AR087744A1 (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa | |
| UY32236A (es) | Compuestos de arilo sustituidos y su uso | |
| BRPI0415713A (pt) | mio-inositol hexafosfato para uso tópico | |
| BR112014026442A8 (pt) | combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica. | |
| ECSP088408A (es) | Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico | |
| PA8627601A1 (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos | |
| BR112013019876A2 (pt) | formulação farmacêutica, uso da formulação farmacêutica, frasco e kit | |
| BR112014012180A2 (pt) | composições farmacêuticas compreendendo álcool perilílico, álcool iso-perilílico e seus derivados enriquecidos de deutério | |
| BR112013010345A2 (pt) | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção | |
| BRPI0815280A2 (pt) | medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf | |
| BR112013025410A2 (pt) | tratamento terapêutico | |
| BRPI0620983B8 (pt) | uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico | |
| CY1112814T1 (el) | Αντιμετωπιση ανθεκτικων στα φαρμακα ογκων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |